Coverage
-
September 13, 2021
Investors in Ophthotech Corp. asked a New York federal judge Friday to approve a $29 million cash settlement they had reached with the biopharmaceutical company over claims that it misled shareholders regarding clinical trial phases for a macular degeneration drug.
1 other articles on this case.
View all »